Who
Carole Nuechterlein
Director
Company insider
Files Form 4 as: Director and 10% owner, Aligos Therapeutics; Director, Entrada Therapeutics; Director, Tempest Therapeutics; Director, AveXis.
In numbers
- Trades disclosed
- 24
- Buys
- 1
- Sells
- 0
- Bought
- $6.0M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 10 Feb 2016
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 25 Jun 2025filed 26 Jun 2025 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,860 at $0.00 | filing |
| 27 Jun 2024filed 28 Jun 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 28 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,411 at $0.00 | filing |
| 27 Feb 2024filed 28 Feb 2024 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 25 Oct 2023filed 27 Oct 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | $516K3,966,800 at $0.13 | filing |
| 25 Oct 2023filed 27 Oct 2023 | ALGS Aligos TherapeuticsBiotechnology | SEC FORM 4 Bought | $6.0M7,933,601 at $0.76 | filing |
| 20 Jul 2023filed 21 Jul 2023 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2022filed 27 Jun 2022 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 2 Jun 2022filed 6 Jun 2022 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,918 at $0.00 | filing |
| 28 Oct 2021filed 1 Nov 2021 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,552 at $0.00 | filing |
| 17 Jun 2021filed 17 Jun 2021 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 20 Oct 2020filed 20 Oct 2020 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,145,991 at $0.00 | filing |
| 20 Oct 2020filed 20 Oct 2020 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —662,799 at $0.00 | filing |
| 20 Oct 2020filed 20 Oct 2020 | ALGS Aligos Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —283,550 at $0.00 | filing |
| 20 Oct 2020filed 20 Oct 2020 | ALGS Aligos TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,145,991 | filing |
| 20 Oct 2020filed 20 Oct 2020 | ALGS Aligos TherapeuticsBiotechnology | SEC FORM 4 Code C | —662,799 | filing |
| 20 Oct 2020filed 20 Oct 2020 | ALGS Aligos TherapeuticsBiotechnology | SEC FORM 4 Code C | —283,550 | filing |
| 22 Jun 2020filed 23 Jun 2020 | TPST Tempest Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.